How I explore... outcomes in clinical trials: Comments about recent studies of cardiovascular prevention;Comment j'explore... les critères de jugement dans les essais cliniques: Réflexions à propos d'études récentes de prévention cardio-vasculaire

Revue Medicale de Liege

Volumn 61, Issue 4, 2006, Pages 260-266

  Scheen, A J ^a,b,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Service de Diabétologie Nutrition et Maladies Métaboliques   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cardiovascular prevention; Drug; Efficacy; Evidence based medicine; Outcomes; Randomised clinical trials

Indexed keywords

AMLODIPINE; ATENOLOL; ATORVASTATIN; PIOGLITAZONE; PLACEBO; SIMVASTATIN; VALSARTAN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; MORTALITY; PREVENTIVE MEDICINE; REVIEW; THERAPY EFFECT; RISK FACTOR;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; RISK FACTORS;

EID: 33745041066     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Scheen AJ.- Evidence-based medicine. Apport des essais cliniques contrôlés. Rev Med Liège, 2000, 55, 216-219.
2. Delvenne C, Pasleau F.- Comment résoudre en pratique un problème diagnostique ou thérapeutique en suivant une démarche EBM? Rev Med Liège, 2000, 55, 226-232.
3. Van den Bruel A, Chevalier P, Vermeire E, et al.- Evidence-Based Medicine. Otite moyenne chez l'enfant. Comment formuler une question PICO? Rev Med Liège, 2004, 59, 671-675.
4. Scheen AJ.- La mesure de l'efficacité thérapeutique, étape essentielle dans la médecine factuelle. Rev Med Liège, 2000, 55, 206-210.
5. Kuller LH.- Clinical trials: surrogate endpoints or hard endpoints? Am J Cardiol, 2001, 88 (suppl), 59E-61E.
6. LaRosa JC, Grundy SM, Waters DD, et al.- Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005, 352, 1425-1435.
7. Pedersen TR, Faergeman O, Kastelein JJP, et al. The Increment Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.- High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA, 2005, 294, 2437-2445.
8. The FIELD study investigators.- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005, 366, 1849-1861.
9. Dahlöf G, Sever P, Poulter N, et al.- Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes trials: Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 2005, 366, 895-906.
10. Dormandy J, Charbonnel B, Eckland DJA, et al, on behalf of the PROactive investigators.- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitA-zone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet, 2005, 366, 1279-1289.
11. Scheen AJ.- Treating to New Targets: plaidoyer pour une valeur cible de cholestérol LDL égale ou inférieure à 75 mg/dl chez tout patient coronarien. Rev Med Liège, 2005, 60, 264-267.
12. Scheen AJ.- L'étude IDEAL comparant simvastatine 20-40 mg versus atorvastatine 80 mg en prévention après un infarctus du myocarde: entre deux idées de l'idéal. Rev Med Liège, 2006, 61, 53-59.
13. Radermecker RP, Scheen AJ.- L'étude FIELD de protection cardio-vasculaire avec le fénofibrate chez le patient diabétique de type 2. Rev Med Liège, 2005, 60, 957-961.
14. Krzesinski JM.- Première démonstration d'une supériorité des agents antihypertenseurs modernes par rapport aux molécules plus anciennes dans la prévention cardio-vasculaire: résultats du bras "abaissement de pression artérielle" de l'étude ASCOT. Rev Med Liège, 2005, 60, 820-826.
15. Scheen AJ, Lefèbvre PJ.- L'étude PROactive: prévention secondaire des accidents cardio-vasculaires par la pioglitazone chez le patient diabétique de type 2. Rev Med Liège, 2005, 60, 896-901.
16. Freemantle N.- Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? BMJ, 2001, 322, 989-991.
17. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C.- Composite outcomes in randomized trials. Greater precision but with greater uncertainty? JAMA, 2003, 289, 2554-2559.
18. Nissen SE, Nicholls SJ, Sipahi I, et al.- Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA, 2006, 95, online March 13 (doi:10.1001/jama.295.13.jpc60002).
19. Taylor A, Shaw LJ, Fayad Z, et al.- Tracking atherosclerosis regression: a clinical tool in preventive cardiology. Atherosclerosis, 2005, 180, 1-10.
20. Julius S, Kjeldsen SE. Weber M for the VALUE trial group.- Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004, 363, 2022-2031.
21. The FIELD Study Investigators.- The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovascular. Diabetohgy, 2004, 3, 9 (doi:10.1186:1475-2840-3-9).
22. Yki-Järvinen H.- The PROactive study: some answers, many questions (Editorial). Lancet, 2005, 366, 1241-1242.
23. Freemantle N.- How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events? BMJ, 2005, 331, 836-838.
24. Cannon CP, Braunwald E, McCabe CH, et al.- Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004, 350, 1495-1504.
25. Cannon CP.- The IDEAL cholesterol. Lower is better (Editorial). JAMA, 2005, 294, 2492-2494.
26. Scheen AJ.- Interruption prématurée des études ASCOT et CARDS de prévention cardio-vasculaire avec l'atorvastatine chez le sujet hypertendu ou diabétique: compromis entre éthique et statistique en médecine factuelle. Rev Med Liège, 2003, 58, 585-590.
27. Pfeffer MA, Swedberg K, Granger CB, et al.- Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003, 362, 759-766.
28. Kulbertus H.- L'étude CHARM. Rev Med Liège, 2003, 58, 646-652.
29. Lubsen J, Kirwan BA.- Combined endpoints: can we use them? Stat Med, 2002, 21, 2959-2970.